Bionano Genomics, Inc. — Form 8-K
Filed August 10, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 38/100
What the filing says
Bionano reported Q2 2026 revenue of $8.2M (21% YoY growth; consumables up 31% to $4.3M) with 53% gross margin. The company fully retired all outstanding Senior Secured Convertible Debentures (previously $9.979M liability as of Dec 31, 2025), eliminating secured debt and liens. However, cash and equivalents fell from $2.990B to $3.730B, investments declined $10.1M to $6.189M, and accumulated deficit widened to $735.3M. Full-year 2026 guidance: $31–$33M revenue.
Why this rating
Revenue growth and debt elimination are operationally positive; cash burn and shrinking liquidity offset gains. Relative to $12.2M market cap, $8.2M quarterly revenue is large; debt payoff removes risk. But the company remains deeply unprofitable and cash-constrained for its size.
See more from August 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.